APRE vs. VTGN, IMAB, PYRGF, THTX, ADAG, ANL, PMVP, EPIX, MURA, and TLSA
Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Vistagen Therapeutics (VTGN), I-Mab (IMAB), PyroGenesis Canada (PYRGF), Theratechnologies (THTX), Adagene (ADAG), Adlai Nortye (ANL), PMV Pharmaceuticals (PMVP), ESSA Pharma (EPIX), Mural Oncology (MURA), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry.
Aprea Therapeutics vs.
Aprea Therapeutics (NASDAQ:APRE) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings.
In the previous week, Vistagen Therapeutics had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 1 mentions for Vistagen Therapeutics and 0 mentions for Aprea Therapeutics. Vistagen Therapeutics' average media sentiment score of 0.01 beat Aprea Therapeutics' score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.
34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are held by institutional investors. 12.8% of Aprea Therapeutics shares are held by insiders. Comparatively, 1.3% of Vistagen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Aprea Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.
Aprea Therapeutics has higher earnings, but lower revenue than Vistagen Therapeutics. Vistagen Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vistagen Therapeutics received 227 more outperform votes than Aprea Therapeutics when rated by MarketBeat users. Likewise, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 56.70% of users gave Aprea Therapeutics an outperform vote.
Aprea Therapeutics currently has a consensus price target of $15.50, indicating a potential upside of 491.60%. Given Aprea Therapeutics' higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Vistagen Therapeutics.
Aprea Therapeutics has a net margin of -1,029.50% compared to Vistagen Therapeutics' net margin of -6,777.08%. Vistagen Therapeutics' return on equity of -48.12% beat Aprea Therapeutics' return on equity.
Summary
Vistagen Therapeutics beats Aprea Therapeutics on 13 of the 19 factors compared between the two stocks.
Get Aprea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aprea Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APRE) was last updated on 2/22/2025 by MarketBeat.com Staff
Free APRE Stock Alerts